GLPG0634 analog NEW
| Price | $34 | $48 | $80 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: GLPG0634 analog | CAS No.: 1206101-20-3 |
| Purity: 99.22% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | GLPG0634 analog |
| Description | GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively. |
| Kinase Assay | EC50 values of the test compounds are calculated from serial dilution series ranging from 200 to 0.1 μM. Cells are seeded in 96-well plates at a density of 5,000 cells per well in 100 μL medium. The next day, 100 μL medium containing each test compound is added. Cells are incubated for 16 h, fixed and processed for automated microscopy. EC50 estimates are calculated using four-parameter log-logistic fit with the package drc[1]. |
| In vitro | In multiple cell lines, GLPG0634 inhibited IFN-αB2-induced JAK1/TYK2 type II receptor signaling and IL-2/4-induced JAK1/JAK3/γc signaling (IC50: 150-760 nM). At the cellular level, GLPG0634 was more selective for JAK1-containing JAK/STAT signaling than JAK2 kinase. In addition, GLPG0634 inhibited the proliferation of Th1/Th2/Th17 cells. |
| In vivo | In multiple cell lines, GLPG0634 inhibited IFN-αB2-induced JAK1/TYK2 type II receptor signaling and IL-2/4-induced JAK1/JAK3/γc signaling (IC50: 150-760 nM). At the cellular level, GLPG0634 was more selective for JAK1-containing JAK/STAT signaling than JAK2 kinase. In addition, GLPG0634 inhibited the proliferation of Th1/Th2/Th17 cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 7.5 mg/mL (18.27 mM), Sonication is recommended. |
| Keywords | GLPG0634 | Inhibitor | AK-STAT | GLPG-0634 | JAK | GLPG0634 analog | Janus kinase | inhibit | Hela cell | GLPG 0634 | GLPG-0634 analog | OSM/IL-lβ |
| Inhibitors Related | Delgocitinib | Deucravacitinib | Fedratinib | Ruxolitinib | Tofacitinib Citrate | GSK 3 Inhibitor IX | Ibrutinib | Ruxolitinib phosphate | JAK-IN-10 | Baricitinib | Tofacitinib | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | JAK-STAT Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-01-17 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2024-10-30 | |
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-01-16 | |
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY